Abstract: Provided is a method for treating cancer by combining an alkylating agent prodrug and a cell cycle inhibitor. The alkylating agent prodrug may be a prodrug of an AKR1C3 enzyme-activated alkylating agent or a prodrug of a hypoxia-activated alkylating agent. The cell cycle inhibitor may be a CDK inhibitor, a WEE inhibitor, a CHK inhibitor, or an ATR inhibitor.

Abstract: An AKR1C3-activated DNA alkylating agent having any one of the following structural formulae (A, B, C), or a pharmaceutically acceptable salt thereof, or a prodrug thereof, or a solvate thereof, or an isotopic variant thereof, and an anticancer medical application thereof.

Abstract: The present invention provides a method for treating cancer patients accompanied by pain by combining an AKR1C3-activated anticancer prodrug compound with an analgesic drug, a pharmaceutical use, a drug combination and a pharmaceutical formulation thereof, which provides a reasonable alternative for clinical cancer treatment. In particular, the combination of AST-3424 and non-steroidal analgesic drug can achieve the effect of simultaneously treating cancer and relieving pain.

Abstract: Described is a fluorine-containing compound shown in Formula II/III and its anti-cancer medical use. The present application creatively introduced the fluorine-containing groups such as special trifluoromethyl groups, fluorine-substituted aryl groups, or heteroaryl groups at special positions (such as the position between the nitrobenzene ring and the phosphate amine group) in the structures of the above compounds. After this modification, it was found that all of the resulting compounds were solids (including waxes).

Abstract: The present invention provides a treatment method for treating a PARP inhibitor-resistant patient with TH-302 alone or in combination, a drug, and a pharmaceutical use thereof. The drug may contain a hypoxia activated compound of formula (I) as follows: where each R is independently selected from H, —CH3 and —CH2CH3, and each X is independently selected from Cl, Br, MsO, TsO and other leaving functional groups.

Abstract: The present disclosure relates to a heterojunction solar cell, including a substrate layer, a first passivation layer, a second passivation layer, an emission member, and a back surface field member. The emission member and the back field member each include a doped layer, a conducting layer, and an electrode layer sequentially disposed along the direction away from the substrate layer. One or both of the emission member and the back surface field member include an electrical contact reinforced structure. The electrical contact reinforced structure is a first doped region and a second doped region of the doped layer. The second doped region is disposed beside the first doped region and is shielded by the electrode layer. One or both of the doping concentration and the crystallization degree of the second doped regions are higher than those of the first doped region.

Abstract: A preparation method of a heterojunction solar cell includes following steps: depositing a first passivation layer on a first surface of a silicon substrate by using a gas source, a base material of the first passivation layer being hydrogenated amorphous silicon; during depositing hydrogenated amorphous silicon of the first passivation layer, allowing the gas source to gradually incorporate carbon dioxide, and controlling a proportion of carbon dioxide in the gas source to gradually increase with increase of a thickness of the first passivation layer which has been deposited.

Abstract: The present invention provides a method for treating a cancer by using TH-302 and an analogue thereof alone or in combination with a PARP inhibitor, wherein in particular, TH-302 is used alone for treating a cancer patient sensitive to the PARP inhibitor, and TH-302 is used in combination with the PARP inhibitor for treating a cancer patient.

Abstract: A method for treating cancer and tumor patients having KRAS mutations, and pharmaceutical use.

Abstract: A method for treating BRCA gene-mutated cancer. In the method, a drug containing hypoxia-activated prodrug compounds of formulas (1), (2) and (3) or AKR1C3 enzyme-activated prodrug compounds of formulas (4), (5), (6), (7), (8), (9), (10), (11) and (12) and salts, esters, solvates and isotopic isomers thereof, is used alone or in combination with other drugs to treat patients with BRCA gene-mutated cancer and tumors.

Abstract: The present invention provides gemcitabine anticancer derivatives of formula (III), which have the potential to be developed into AKR1C3-activated anticancer drugs, and the anticancer pharmaceutical use thereof,.

Abstract: Provided are the use of the compound 1-(3-(3-N,N-dimethylaminocarbonyl)phenoxyl-4-mtrophenyl)-1-ethyl-N,N?-bis(ethylene)phosphoramidate, or a pharmaceutically acceptable salt, isotopic variant or solvate thereof in the manufacture of a medicament for treating cancer, and a composition which comprises the above compound and at least one anti-cancer drug.

Abstract: A preparation method of a heterojunction solar cell includes following steps: depositing a first passivation layer on a first surface of a silicon substrate by using a gas source, a base material of the first passivation layer being hydrogenated amorphous silicon; during depositing hydrogenated amorphous silicon of the first passivation layer, allowing the gas source to gradually incorporate carbon dioxide, and controlling a proportion of carbon dioxide in the gas source to gradually increase with increase of a thickness of the first passivation layer which has been deposited.

Abstract: A solar cell is provided, includes: a substrate, a first passivation layer, an emission layer, a first conductive layer, a second passivation layer, a back surface field layer and a second conductive layer. The first passivation layer, the emission layer and the first conductive layer are sequentially disposed on a surface of one side of the substrate, and the second passivation layer, the back surface field layer and the second conductive layer are sequentially disposed on a surface of another side of the substrate. The first conductive layer includes a first transparent conductive oxide layer, a first conductive metal layer and a second transparent conductive oxide layer which are sequentially stacked.

Abstract: The present application provides a transparent conductive oxide film and a heterojunction solar cell, which relates to the technical field of solar cells. The transparent conductive oxide film includes a seed layer, a conductive layer and a protection layer. The seed layer includes an indium tin oxide film or a gallium/aluminum co-doped zinc oxide film. The conductive layer is a gallium/aluminum co-doped zinc oxide film. The protection layer is an indium tin oxide film. The thickness of the indium tin oxide film in the transparent conductive oxide film is smaller than the thickness of the gallium/aluminum co-doped zinc oxide film. It can ensure battery efficiency and reduce battery attenuation, while reducing costs.

Abstract: An AKR1C3 detection method, and a diagnostic kit for detecting AKR1C3 and use thereof. The AKR1C3 detection method includes the following steps: treating a formalin-fixed paraffin-embedded human tissue specimen sequentially using an organic solvent, an alcohol, and water; performing antigen retrieval on the treated formalin-fixed paraffin-embedded human tissue specimen in the presence of an antigen retrieval solution; co-incubating the antigen-retrieved formalin-fixed paraffin-embedded human tissue specimen with a blocking buffer to block a non-specific antigen; mixing the blocked formalin-fixed paraffin-embedded human tissue specimen with a certain concentration of AKR1C3 monoclonal antibody solution for primary antibody incubation, and mixing the primary antibody-incubated formalin-fixed paraffin-embedded human tissue specimen with a certain concentration of a secondary antibody solution for secondary antibody incubation.

Abstract: A photosensitive polyimide resin for ultraviolet curing-based three-dimensional printing, which is prepared from 40-60 parts by weight of an active group-containing polyimide resin; 20-50 parts by weight of an organic activator; and 2-5 parts by weight of a photoinitiator. This application further provides a method for preparing the photosensitive polyimide resin.

Abstract: Described are hypoxia-activated DNA alkylating agents having any one of the following structural formulas, or a pharmaceutically acceptable salt, a prodrug, a solvate or an isotopic variant thereof, as well as an anticancer medical use thereof.

Abstract: A compound of formula (I), or pharmaceutically acceptable salts, solvates, isotopic variants, or isomers thereof, and anticancer medical use are provided.

Abstract: Described are compounds that act as AKR1C3 inhibitors or pharmaceutically acceptable salts or solvates or isotopically substituted compounds thereof and methods thereof.